(Q37960909)

26 August 2017

Current treatment of metastatic bladder cancer and future directions (English)

1 reference

26 August 2017

1 reference

Amy Q Lei

1

1 reference

PubMed ID

22117153

26 August 2017

Liang Cheng

series ordinal

2

1 reference

PubMed ID

22117153

26 August 2017

Chong-xian Pan

series ordinal

3

1 reference

26 August 2017

1 December 2011

1 reference

Expert Review of Anticancer Therapy

26 August 2017

1 reference

26 August 2017

11

1 reference

26 August 2017

1851-1862

1 reference

26 August 2017

12

1 reference

26 August 2017

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

The treated natural history of high risk superficial bladder cancer: 15-year outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

The impact of variant histology on the outcome of bladder cancer treated with curative intent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Micropapillary bladder cancer: a review of Léon Bérard Cancer Center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced B

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

A request for nondisclosure: don't tell mother.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Successful management of metastatic urothelial carcinoma with gemcitabine and Paclitaxel chemotherapy in a hemodialysis patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Molecular targets and targeted therapies in bladder cancer management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Evaluation of epidermal growth factor receptors in bladder tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Phase II study of sunitinib in patients with metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Self-regulation of growth in three dimensions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Squamous cell carcinoma of bladder. A review of 114 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Pure squamous cell carcinoma of the bladder in western countries. Report on 19 consecutive cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

A phase II study of gemcitabine plus cisplatin chemotherapy in advanced bilharzial bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Primary chemotherapy with low-dose prolonged infusion gemcitabine and cisplatin in patients with bladder cancer: a Phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Small-cell carcinoma of the urinary bladder: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Human microdosing for the prediction of patient response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Implications of cancer stem cells in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.181

21 January 2018

Identifiers

DOI

10.1586/ERA.11.181

1 reference

26 August 2017

1 reference

PubMed ID

22117153